# First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

> **NCT06128382** · PHASE1 · COMPLETED · sponsor: **Osivax** · enrollment: 48 (actual)

## Conditions studied

- Coronavirus

## Interventions

- **BIOLOGICAL:** OVX033
- **BIOLOGICAL:** Saline solution

## Key facts

- **NCT ID:** NCT06128382
- **Lead sponsor:** Osivax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-08
- **Primary completion:** 2024-07-08
- **Final completion:** 2024-11-29
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06128382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06128382, "First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06128382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*